Open-Label, Randomized, Phase 2 Study Of Sapanisertib (Tak-228/Mln0128) In Combination With Fulvestrant In Postmenopausal Women With Estrogen Receptor-Positive (Er Plus )/Human Epidermal Growth Factor Receptor-2-Negative (Her2-) Advanced Or Metastatic Breast Cancer (Mbc) That Previously Progressed During Or After Aromatase Inhibitor Therapy (Nct02756364)